



Carolee A. King, JD
Senior Vice President & General Counsel

Office of Legal and Regulatory Affairs
301 University Blvd.
Galveston, TX 77555-0124
O 409.772.1904 F 409.772.5064
E caaking@utmb.edu

February 11, 2016

Dear Manufacturers,

I am writing on behalf of University of Texas Medical Branch (UTMB) (340B ID DSH450018) to inform manufacturers that UTMB recently underwent an audit by the Health Resources and Services Administration (HRSA) of UTMB's compliance with 340B Drug Pricing Program (340B Program) requirements.

As background, UTMB qualifies for the 340B Program as a disproportionate share hospital in Galveston, Texas and has participated in the 340B Program since April 1, 1994.

Through the audit process, HRSA found UTMB to have non-compliance within its 340B Program and responsible for repayment as a result of the following finding:

UTMB dispensed 340B drugs to ineligible individuals, as prohibited by 42 USC 256b(a)(5)(B).

UTMB has identified all affected manufacturers and will notify each of them concerning these violations and begin a dialogue on a method for repayment. If manufacturers do not receive notification from UTMB and believe repayment may be owed for the violations described in this letter, or if you have any questions or comments regarding the violations described in this letter, please contact:

Brad Willbanks
Associate Vice President and Deputy Chief Compliance Officer
The University of Texas Medical Branch
301 University Blvd.
Galveston, TX 77555-0198
(409)-747-8706

Very truly yours,

Carolee A. King
Senior Vice President & General Counsel
The University of Texas Medical Branch

{D0647404.DOCX / 1 }

